Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Lung Neoplasms 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Congenital Abnormalities 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Breast Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Trastuzumab 597Paclitaxel 562Cyclophosphamide 545Docetaxel 479Capecitabine 388Letrozole 350Fulvestrant 311Doxorubicin 285Carboplatin 277Tamoxifen 257Anastrozole 219exemestane 211Epirubicin 210Radiotherapy 197Bevacizumab 189pertuzumab 177Gemcitabine 163Vinorelbine 162pembrolizumab 161Lapatinib 161palbociclib 152Exercise 132Fluorouracil 118Albumin-Bound Paclitaxel 116eribulin 108Magnetic Resonance Spectroscopy 108130-nm albumin-bound paclitaxel 107Everolimus 103Taxes 96Cisplatin 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Breast Neoplasms × Drug Screening Assays, Antitumor × Clear all
NCT00003253 2013-12-19

Evaluation of Drug Resistance in Patients With Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
100 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡